Introduction
Pre-exposure prophylaxis-the use of antiretroviral drugs by non-infected people to prevent the acquisition of HIVis a promising prevention option.
HIV prevention strategies that include both targeted and broad "test and treat" interventions have not had the predicted impact on the HIV epidemic. 1 Modeling studies suggest that pre-exposure prophylaxis has the potential to curtail the HIV epidemic when used as part of a combination public health prevention strategy. [2] [3] [4] The estimated number needed to treat to prevent one new infection might be as low as 13 when pre-exposure prophylaxis is given to a group at high risk of HIV (for example, incidence of 9%). 5 Effectiveness studies and open label extension demonstration projects in high and low income settings have shown that pre-exposure prophylaxis can be delivered feasibly within existing health systems. 6 However, uptake, reimbursement packages, and provision of pre-exposure prophylaxis vary between countries where national programs have been established.
Early data from San Francisco suggest that the roll-out of pre-exposure prophylaxis, in combination with other strategies, has been associated with a decline in the incidence of HIV, despite slow initial uptake. 7 By the end of such as private or national Medicaid programs. Uptake was slow initially, followed by acceleration and then a steady state (conference presentation). 14 Data from the cross sectional National HIV Behavioural Surveillance (NHBS) system found that only 4% of surveyed men who have sex with men reported using pre-exposure prophylaxis, but more than half reported that they would be willing to take it. 15 A program in New South Wales in Australia enrolled more than 6500 participants over a 70 week period with steady enrollment. 16 In France, 2805 people started pre-exposure prophylaxis in the first year of the program (conference presentation). 17 Data are emerging on uptake from other national programs.
Sources and selection criteria
This review extends a comprehensive systematic literature review and meta-analysis by Fonner and colleagues that included all literature on pre-exposure prophylaxis published in peer reviewed journals or presented at a scientific conference between 1 January 1990 and 15 April 2015. 18 Key outcomes included HIV infection, adverse events, antiretroviral drug resistance, and any effects on the effectiveness of hormonal contraception, pregnancy, or sexual behavior. The Fonner review covered randomized controlled trials (RCTs), open label extension trials, and demonstration projects that evaluated oral prophylaxis containing TDF to prevent HIV infection. All studies measured one or more key outcomes and compared people randomized to pre-exposure prophylaxis versus placebo or no prophylaxis.
We replicated the methodology, including the search terms, used by the Fonner review, although the search and data extraction were performed by one person instead of two. We included studies published in peer reviewed journals or presented at a scientific conference between 16 April 2015 and 19 September 2016. Only English language and human studies were included. The following databases were searched: PubMed, Embase, and CINAHL. For conference abstracts we searched the Database of Citations Index. We also performed iterative secondary reference searching on all included studies.
In addition to the data extracted in the Fonner review, and updated here, we extracted data on cost effectiveness and breakthrough infections.
Results of the Fonner evidence review
The Fonner review screened 3068 citations, including 39 articles and six conference abstracts describing 18 relevant studies, 15 of which were RCTs and three were observational open label extension trials or demonstration projects. Seven of the RCTs were double blinded placebo controlled trials of daily oral pre-exposure prophylaxis, two studies randomized participants to immediate or delayed pre-exposure prophylaxis, and one study compared daily pre-exposure prophylaxis with placebo and "no pills."
In our extended literature review of articles published between April 2015 and September 2016, we screened a further 1271 citations. Eight articles and two conference abstracts covering further data on six of the studies identified in the Fonner review were included (fig 1) . This ensure that those who might benefit can access it without experiencing stigma.
This review assesses the evidence on the effectiveness, safety, and risk compensation (see Glossary) of pre-exposure prophylaxis. It provides an overview of adherence, adverse events, risk behaviors, breakthrough infections, and cost effectiveness. National and international guidelines are detailed and an overview of alternative drug regimens is provided.
Incidence and prevalence of HIV
In 2016, an estimated 36.7 million (30.8-42.9 million) adults and children were living with HIV in the world, with a prevalence of 0.8 (0.7-0.9) among people aged 15-49 years. In 2016, an estimated 1.8 million (1.6-2.1 million) people globally were newly infected with HIV, 13 giving an incidence of 0.43 per 1000 population (people aged 15-49 years), and the number dying was 1.0 million (0.83-1.2 million). 13 Data on the uptake of pre-exposure prophylaxis within programs are available through prescription data and health service data. In the United States, an analysis of electronic prescription data from about 80% of retail pharmacies between 2012 and 2016 by Gilead (manufacturer of Truvada, the most commonly used form of pre-exposure prophylaxis: emtricitabine (FTC)-tenofovir disoproxil fumarate (TDF)) found that 98 732 people started prophylaxis during this period. It estimated that 136 000 people were on prophylaxis by the end of the second quarter of 2017 (conference presentation).
14 These data do not include non-retail pharmacy prescriptions,
GLOSSARY
Breakthrough infection: HIV infection in a person fully adherent to pre-exposure prophylaxis Combination prevention: programs that use a mix of biomedical, behavioral, and structural interventions Emtricitabine (FTC): an antiretroviral agent used in preexposure prophylaxis Open label extension (OLE): typically, a follow-on of a placebo controlled clinical trial, where all participants are given an open label study drug (both they and the investigators know the drug is active and not a placebo) Pre-exposure prophylaxis (PrEP): the use of antiretroviral drugs by people who are not infected with HIV to prevent acquisition of HIV Risk compensation: adjustment of behavior in response to perceived changes in risk; in the case of pre-exposure prophylaxis, this would result in protection causing people to increase sexual behavior that may involve exposure to HIV Serodifferent partnership: one partner is infected with HIV and the other is not Seroconcordant partnership: both partners are infected with HIV, or both partners are uninfected Treatment as prevention: the public health strategy of treating HIV infected people to reduce HIV incidence in the population Tenofovir disoproxil fumarate (TDF): an antiretroviral agent used in pre-exposure prophylaxis Waitlisted trial: trial design where participants receive the intervention immediately or after a deferred period cious and effective in men who have sex with men. A meta-analysis that compared prophylaxis versus placebo for rectal exposure found a 0.34 (0.15 to 0.80; P=0.01) reduction in the risk of HIV transmission. 18 However, with high adherence this risk reduction is probably greater. Few data exist for trans-populations, although several of the studies described below included trans-men and women. Only one small study has looked at pre-exposure prophylaxis using TDF alone for men who have sex with men. No infections were seen in men who received active prophylaxis, but six emergent infections were found in the placebo arm and deferred phases of the study. 32 One phase III placebo controlled randomized trial assessed the efficacy of daily pre-exposure prophylaxis (iPrEx), 27 one phase III open label RCT evaluated the effectiveness of daily pre-exposure versus none (PROUD), 19 and one phase III placebo controlled randomized trial evaluated the efficacy of "on demand" preexposure prophylaxis (IPERGAY) in men who have sex with men (table 1) . 30 The largest study of daily oral pre-exposure prophylaxis among men who have sex with men is the iPrEx study. 27 This high quality phase III randomized double blind placebo controlled multicenter trial studied 2499 men who have sex with men and transgender male-tofemale adults in Peru, Ecuador, Brazil, Thailand, South Africa, and the US. Participants were randomly assigned to daily FTC-TDF (1251 participants) or placebo (1248 participants). Participants were followed up every four weeks with interview, HIV testing, risk reduction counseling, adherence, pill count, and dispensing of pills and condoms for a total of 3324 person years. The primary outcome was HIV infection. Over the course of the study 100 participants became infected with HIV; 36 in the FTC-TDF group and 64 in the placebo group, representing a 44% (15% to 63%) reduction in HIV incidence using a modified intention to treat (ITT) analysis. After adjustment for the age difference between the two groups, efficacy was estimated to be 43% (14% to 62%).
The PROUD study was the first to explore the real world effectiveness of daily oral pre-exposure prophylaxis in men who have sex with men, 19 and the full results of the randomized phase of the study were published after the Fonner review. This phase III randomized open label waitlisted trial (see Glossary) was conducted in 544 HIV negative men who have sex with men at 13 sexual health clinics in England. Participants were randomly assigned to receive daily FTC-TDF immediately (275 participants) or after a deferral period of 12 months (269 participants). Participants were followed up every three months with an HIV test and screening for sexually transmitted infections (STIs). After an interim analysis, the study was halted early and all participants who were still in the deferral period were offered the study drug. A total of 243 person years of follow-up in the immediate group and 222 person years of follow-up in the deferred group had accumulated. Twenty three participants were infected with HIV during the period of randomized trial observation; three in the FTC-TDF group and 20 in the deferred (no prophylaxis) group, representing a rate difference in HIV infection of 7.8 per 100 person years (90% confidence extended literature review provides published results of the PROUD 19 20 and IPERGAY studies (conference presentation (reference 21)) 21 22 ; additional safety data from the iPrEx, 23 Partners PrEP, 24 25 and VOICE 26 studies; and updated sexual behavior data from the IPERGAY study.
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Recent evidence for pre-exposure prophylaxis Overview of evidence of efficacy The Fonner review showed that oral pre-exposure prophylaxis containing TDF based regimens is highly effective in preventing the transmission of sexually acquired HIV infection across different risk groups. 18 The meta-analysis of 11 RCTs that compared pre-exposure prophylaxis with placebo estimated a 51% reduction in risk of HIV infection (risk ratio 0.49, 95% confidence interval 0.33 to 0.73) in the intention to treat analysis; all randomized participants were included regardless of adherence except those who were acutely infected with HIV at baseline. Table 1 summarizes the studies of the effectiveness of oral HIV pre-exposure prophylaxis and fig 2 places these in the context of other HIV prevention options. Adherence (the proportion of people in the active arms with detectable prophylaxis drugs in their blood) was strongly associated with effectiveness. The effectiveness of prophylaxis did not depend on sex, route of exposure (penile or vaginal v anal), or age.
Groups studied Men who have sex with men
Evidence from high quality placebo controlled randomized trials, an open label RCT that compared pre-exposure prophylaxis with none, and open label extension trials shows that TDF-FTC prophylaxis is highly effica- Of 414 participants who were randomized to the trial, 400 participants who did not have HIV infection were enrolled to receive an on demand regimen of Truvada or placebo. 30 This regimen involved taking two pills (2×300 mg TDF, 2×200 mg FTC) 2-24 hours before sex, and continuing with a daily pill during periods of sexual risk, followed by post-exposure pills 24 hours and 48 hours after the last sexual exposure. The study was unblinded at interim review owing to the high efficacy of the drug, which conferred a relative risk reduction of 86% (95% confidence interval 40% to 98%).
One phase II safety trial (the US MSM Safety Trial) compared TDF with placebo using a randomized double blind placebo controlled waitlisted design in 400 HIV negative men who have sex with men. 32 Participants were randomized in a 1:1:1:1 design to receive TDF or placebo interval 4.3 to 11.3) in the modified ITT analysis and a relative risk reduction of 86% (64% to 96%). The number needed to treat over one year was 13 (9 to 23). The incidence of HIV in the no prophylaxis group was 9 per 100 person years compared with 1.2 per 100 person years in the prophylaxis group. The incidence of HIV in the no prophylaxis group was markedly higher than that seen in men who have sex with men attending sexual health clinics in England, showing that the study had recruited a group at especially high risk of HIV infection. 42 The third trial to show a significant reduction in HIV infections with pre-exposure prophylaxis was the phase III randomized placebo controlled multicenter IPERGAY trial of pre-exposure prophylaxis for men who have sex with men, which evaluated an event based oral TDF-FTC regimen versus placebo. Full results were published after men, especially those in black, Asian, and minority ethnic groups, who have a disproportionately high risk of HIV. Retention in the study was 98%. However, self reported and drug level based adherence was low, suggesting low acceptability of the drug intervention. The second was the IAVI Kenya Study, a small safety and adherence study conducted among Kenyan men who have sex with men and female commercial sex workers. Sixty seven men who have sex with men and five female sex workers were randomized to receive daily FTC-TDF or placebo, or intermittent FTC-TDF or placebo in a 2:1:2:1 ratio. There was one seroconversion in the placebo arm. 31 The iPrEx Open Label Extension (iPrEx OLE) trial enrolled 1603 HIV negative men and transgender women who have sex with men who were previously part of preexposure prophylaxis studies (iPrEx, ATN082/P roject PrEPare and US Safety study). 28 Participants were enrolled into the study regardless of whether they took up pre-exposure prophylaxis. Participants were followed up for 72 weeks after enrollment into the open label extension. Seventy six per cent of those enrolled immediately or after nine months. The main endpoints were safety and behavioral effects. No adverse events were associated with TDF prophylaxis and there was no evidence of risk compensation (see Glossary). Participants were followed up with interview, an HIV test, screening for STIs, and risk reduction and adherence counseling every three months for 24 months. No infections were seen among those taking the active drug. Seven participants seroconverted: four in the placebo arm and three in the delayed arm who were not on the study drug. One participant in the placebo group was HIV infected at enrollment.
There have been two smaller studies. The first was a feasibility and acceptability pilot study (Project PrEPare), which recruited 58 men who have sex with men aged 18-22 years in the US. Participants were randomized to receive a behavioral intervention alone, the behavioral intervention plus pre-exposure prophylaxis, or the behavioral intervention plus placebo. No seroconversions were noted among the 58 participants. 29 The study showed the feasibility of enrolling young men who have sex with women using both pre-exposure prophylaxis and hormones. Furthermore, pre-exposure prophylaxis studies that have included transgender women have not been powered to detect HIV incidence in this group or a difference between men who have sex with men and transgender women.
Heterosexuals
The efficacy of pre-exposure prophylaxis in heterosexual populations has been explored in two phase III RCTs in high risk heterosexual women (FEM-PrEP, TDF-2, VOICE), 39 40 one phase III RCT comparing daily prophylaxis with placebo among sero-discordant couples (Partners PrEP), 36 and one open label extension of daily prophylaxis (Partners demonstration project). 37 These studies found that tenofovir based prophylaxis had a high level of efficacy in reducing the risk of HIV transmission in heterosexual populations when adherence to the drug was high. The meta-analysis by Fonner and colleagues estimated the relative risk for HIV infection comparing prophylaxis with placebo for penile or vaginal exposure to be 0.54 (0.32 to 0.90; P=0.02). 18 No studies have evaluated the efficacy of an event based or intermittent regimen in heterosexuals, and to date no RCTs in heterosexuals have been undertaken in high income countries. Although there is no reason to doubt that the biology of transmission is the same worldwide, trials to date have clearly shown that adherence data cannot be extrapolated from one population to another.
The strongest evidence of effectiveness in serodiscordant heterosexual couples was reported in the large multicountry Partners PrEP study. 36 This double blind phase III RCT randomized and followed 4747 couples to single (TDF alone) or dual agent (TDF coformulated with FTC) prophylaxis or placebo. The study provides evidence of clinical efficacy for daily FTC-TDF (75%, 55% to 87%) or TDF (67%, 44% to 81%) in serodiscordant opposite sex couples in sub-Saharan Africa. No significant difference was seen between FTC-TDF and TDF (P=0.23). Although the placebo arm of this study was stopped earlier than anticipated, the finding of no difference between FTC-TDF and TDF was replicated in the Partners PrEP open label extension demonstration project.
In the TDF-2 study, 1219 men and women at high risk of HIV in Botswana were randomized to daily oral FTC-TDF or placebo (conference presentation). 46 The study provided good evidence of the efficacy of prophylaxis (62%, 16% to 83%; P=0.03). However, a third of participants did not complete the follow-up per protocol and 10% were lost to follow-up, resulting in risk of bias.
Two studies, FEM-PrEP 39 and VOICE, 40 found no benefit of prophylaxis in heterosexual women at risk of HIV infection; this was thought to be caused by poor adherence to the study drugs. FEM-PrEP was a phase III double blind RCT conducted in sub-Saharan Africa that randomized 2120 heterosexual women at high risk of HIV to daily oral FTC-TDF or placebo, 2056 of whom were evaluated for efficacy after excluding those with HIV infection at baseline and those who did not undergo follow-up. There was no evidence for the clinical efficacy of daily oral FTCin the open label extension started prophylaxis. Rates of enrollment were higher among those who reported condomless receptive anal intercourse and those who were seropositive for herpes simplex 2 virus. Most participants at risk of HIV who chose to use prophylaxis (defined by condomless receptive anal intercourse, more than one anal intercourse partner, or recent STI (syphilis, gonorrhea, or chlamydia diagnosed at that visit) returned for prophylaxis at 12 weeks, suggesting that they used these drugs during periods of risk.
Similar to the randomized phase of the iPrEx study, no seroconversions occurred in the OLE among participants with protective drug levels in dried blood spots (taken quarterly), which was associated with taking four to seven tablets a week. Retention in the study was not associated with sexual risk behavior. The overall reduction in HIV incidence compared with the group who did not take up prophylaxis in the open label extension trial was non-significant at 49% (−1% to 74%) after adjusting for sexual behavior, but it was significantly lower than the placebo group in iPrEx (51% reduction in HIV incidence, 23% to 69%). 28 The IPERGAY OLE enrolled a total of 362 participants (333 existing users of pre-exposure prophylaxis and 29 new participants) and followed them for 18.4 months (interquartile range (IQR) 17.5-19.1). The study found a marked reduction of 97% in the incidence of HIV in the prophylaxis group from the trial and open label extension combined (three infections in 734 patient years of followup) compared with the placebo arm of the IPERGAY study (14 infections in 212 patient years of follow-up). 21 Transgender women iPrEx is the only study to date to report findings in transgender women, albeit in small numbers and without showing evidence of HIV prevention in this group. Of the 2499 participants, 399 (14%) were classified as transgender women. Among these women, there were 11 HIV infections in the prophylaxis group and 10 in the placebo group (hazard ratio 1.1, 0.5 to 2.7) 43 ; the trend towards lower effectiveness among transwomen corresponded with lower rates of drug detection, especially among those who reported higher risk behavior.
During the iPrEx OLE, 192 transgender women enrolled and were eligible for pre-exposure prophylaxis; 151 (79%) chose to take it. 43 Three seroconversions occurred in transgender women with drug levels equivalent to less than two pills per week, below the level of quantification, or those who were not taking prophylaxis. No seroconversions were seen among transgender women with drug levels equivalent to two to three pills a week or more. Drug concentrations were lower in transgender women using feminizing hormones than in other transgender women and this could reflect lower adherence.
Although ex vivo studies in women have suggested that hormone treatments may increase susceptibility to HIV infection by altering intracellular TDF concentrations, 44 this is a theoretical concern and evidence from studies of antiretroviral interactions with hormonal contraceptives has been reassuring. 45 However, there have been no pharmacological interaction studies done in transgender in studies, and they include self reported adherence, pill counts, and drug concentrations. Drug concentrations can be measured in red blood cells and peripheral blood mononuclear cells. The median half life of tenofovir diphosphate, an active form of the drug, is 17.1 days (IQR 15.7 to 20.2) in red blood cells and 4.2 (3.7-5.2) days in peripheral blood mononuclear cells. Therefore, estimates of both recent and cumulative drug exposure can be generated. Dried blood spots, which contain millions of red blood cells, can be used as a convenient sampling method to quantify adherence. 49 The degree of adherence needed for drug detection depends on the assays used; in most, the use of one or two tablets a week was sufficient for the drug to be detected in the blood. The Fonner review defined the presence of detectable drug levels in >70%, 41-70%, and ≤40% of the study participants as high, moderate, and low adherence. Studies such as FEM-PrEP and VOICE had less than 30% drug detection overall among those randomized to the drug, an adherence level that conferred no protection against HIV. Studies such as Partners PrEP (FTC/TDF arm), where more than 80% of blood samples from those in the active arm had drug detected, showed correspondingly high levels of efficacy. In all studies, in the subset of participants with detectable drug, the HIV risk reduction ranged from 70% to 92%, and risk reduction among men who have sex with men was 99% (96% to 100%) among those whose drug concentrations were commensurate with daily use. 
Alternative drug regimens
Pre-exposure prophylaxis would be more cost effective if the number of tablets taken could be reduced without a loss of HIV prevention activity. One study suggests that some men who have sex with men have periods of higher HIV risk and that they are inclined to take the drugs more intensively during such periods. 51 Such strategic periodic use of prophylaxis might increase impact and lower the overall cost to the health system. Data extrapolated from RCTs [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and pharmacokinetic studies 50 suggest that intermittent dosing with at least four tablets a week or event based dosing with two tablets 24 hours before and one tablet 24 hours and 48 hours after sex protects against the acquisition of HIV during anal sex. Currently, there is no evidence for the effectiveness of these regimens in insertive or receptive vaginal sex.
There are concerns that less than daily dosing might result in lower adherence. However, this was not borne out by a subgroup analysis of the IPERGAY trial, where high levels of TDF and FTC were detected in the first 113 participants who received pre-exposure prophylaxis (86% and 82%, respectively). The efficacy of on demand prophylaxis in the IPERGAY study however was in the context of participants who used a median number of 15 pills a month and had sexual intercourse 10 times a month. Among the subset of 269 participants who systematically or often used 15 pills or fewer during sexual intercourse each month, and who contributed to 134 per-TDF (hazard ratio 0.94, 0.59 to 1.52) for heterosexual women. However, adherence to the study drug was very low in the intervention arm; less than 40% of HIV uninfected women had drug measured in plasma, despite high self reported adherence. Among the women in the intervention arm who seroconverted, drug levels in the blood indicated that fewer than six tablets per week were being used. 39 The VOICE study randomized 5029 women at high risk of HIV infection in sub-Saharan Africa in a phase II double blinded RCT to oral TDF, oral FTC-TDF, vaginal tenofovir gel, or placebo and evaluated 4969 for efficacy after excluding those infected with HIV at baseline. 40 This study found no evidence of clinical efficacy for daily FTC-TDF (1.04, 0.73 to 1.49) or TDF (1.49, 0.97 to 2.29) for heterosexual women. Again, despite high self reported adherence, the study drug was detected in only 30% of those randomized to taking the oral drug.
People who inject drugs
The only placebo controlled trial of pre-exposure prophylaxis in people who inject drugs randomized 2413 participants in Thailand to receive daily oral TDF or placebo. 34 A 48.9% (9.6% to 72.2%; P=0.01) reduction in HIV incidence was seen in the prophylaxis group, with greater efficacy seen in women than in men (78.6/100 person years, 16.8 to 96.7 (P=0.03) in women v 37.6 person years, −17.8 to 67.9 (P=0.15) in men). Efficacy was associated with older age (88.9%, 41.1% to 99.4% (P=0.01) in those aged >40 years v 33.6%, −40.1 to 69.8 (P=0.30) in those aged 20-29 years). Self reported needle sharing was a risk factor for the acquisition of HIV, and most study participants reported sexual activity that could have exposed them to HIV. The trial sites did not provide access to clean injection equipment, which is considered to be the standard of care. The use of prophylaxis was directly observed for most of the study (conference presentation (reference 47)).
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Ethnic groups Black, Asian, and minority ethnic populations, particularly men who have sex with men, are at increased risk of HIV infection in higher income countries. Data on the efficacy of pre-exposure prophylaxis in these populations are limited, and studies are under way to offer such treatment and provide adherence support. The iPrEx study, a sub-analysis of the efficacy of prophylaxis in Hispanic (N=900 on prophylaxis, N=901 on placebo) versus nonHispanic participants (N=351 on prophylaxis, N=342 on placebo) found no difference in efficacy in non-Hispanic versus Hispanic participants (0.48 (0.14 to 1.60) v 0.57 (0.37 to 0.89); P=0.79). 27 In the PROUD and IPERGAY studies, most of the participants (81% and 91%, respectively) were white, and no data are available on efficacy by ethnicity. Table 1 summarizes the studies of the effectiveness of oral HIV pre-exposure prophylaxis
Adherence
The effectiveness of pre-exposure prophylaxis is strongly associated with adherence. Measures of adherence vary the drugs raised questions about the timing of infection because of viral suppression while on prophylaxis. Also, drug resistance testing that is performed after treatment is stopped, as was done in this case, can be falsely negative owing to overgrowth of drug sensitive strains. 56 A particular problem for HIV infections that are undiagnosed at the time of starting prophylaxis is that the drug may drive de novo resistance mutations, particularly where drug adherence is poor and drug levels fluctuate. Fonner and colleagues reviewed results from six trials that reported cases of resistance to FTC or TDF using standardized genotypic laboratory assays. 18 The risk of developing an FTC related mutation among those acutely infected with HIV at enrollment was significantly higher in the group randomized to receive FTC-TDF prophylaxis rather than placebo (risk ratio 3.72, 1.23 to 11.23; P=0.02). The risk of a TDF related mutation was not statistically significantly different between pre-exposure prophylaxis and placebo regardless of the regimen among those acutely infected at enrollment. In addition, six (2%) TDF or FTC resistant infections occurred among 544 postrandomization HIV infections; five in prophylaxis groups and one in a placebo group. Numbers were too small to calculate a pooled relative risk.
These cases highlight the importance of systematic monitoring and surveillance of pre-exposure prophylaxis use and breakthrough infections at a population level.
Adverse events
To date, studies of TDF-FTC prophylaxis provide robust evidence of safety with short term use (two to three years). Fonner and colleagues found no difference in the proportion of adverse events between prophylaxis and placebo groups in 10 placebo controlled RCTs (odds ratio 1.01, 0.99 to 1.03; P=0.27), with no differences seen in subgroup analyses that included mode of acquisition, adherence, sex, drug regimen, dosing, or age. 18 No differences were seen in grade 3 or 4 adverse events when prophylaxis and placebo groups were compared across 11 placebo controlled RCTs (risk ratio 1.02, 0.92 to 1.13; P=0.76). Results were not presented by su bgroup.
The most common side effects reported were gastrointestinal problems, 30 46 headache, 19 and nausea. 19 46 Depression was also commonly reported, but the rates did not differ between the placebo and active arms. 27 Of note, gastrointestinal events were more commonly reported in the prophylaxis group than in the placebo group in the IPERGAY study (14% v 5%; P=0.002), but no such differences were found in the meta-analysis.
Use of TDF-FTC as prophylaxis has been associated with a mild non-progressive decline in creatinine clearance, which is reversible on discontinuation. 27 57 An association between a decline in bone mineral density and FTC-TDF prophylaxis has also been documented, but no evidence has been found of an associated increase in the risk of fracture. The change in bone mineral density occurred by week 24, did not progress with additional use of prophylaxis, and recovered to levels observed in the placebo arm after prophylaxis was stopped. 59 60 son years of follow-up, there were six HIV infections. All of these infections were in the placebo group (incidence 9.3/100 person years, 3.4 to 20.1), with a relative rate reduction of 100% (39% to 100%; P=0.013).
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Breakthrough infections
HIV infections in people receiving prophylaxis during trials were attributed to undiagnosed HIV infection at the time of starting treatment or infections during periods of no or low use of prophylaxis, as indicated by no or low drug concentrations in the blood. Rare breakthrough infections seem to have occurred in clinical practice, possibly as a result of exposure to a multi-drug resistant strain of HIV or an overwhelming inoculation of virus, although such cases from clinical practice are never as well characterized as in clinical trials.
Two multi-class, drug resistant, apparent breakthrough HIV infections have been described. Importantly, clinical and pharmacokinetic data in these cases suggested good long term adherence to FTC-TDF by the patients, 53 54 although the drug concentrations were measured several weeks after the patients switched from pre-exposure prophylaxis to fully suppressive antiretroviral therapy. One patient was not tested for HIV in the two months before starting prophylaxis (usual standards require HIV testing within seven days). The other patient had missed all of his follow-up appointments after receiving a prophylaxis prescription.
More recently, a breakthrough infection with wild-type virus was reported from the AmPrEP study in a participant with high self reported adherence and high drug levels detected on dried blood spot testing. 55 This participant's viral load was undetectable while on prophylaxis; the rising viral load several weeks after stopping The Partners PrEP demonstration follow-up project reported that condomless sex acts in the main partnership decreased compared with the RCT phase, but there was a slight increase in condomless sex acts outside the main partnership. Nevertheless, rates of STIs and pregnancy did not change. 65 In iPrEx OLE, self reported risk behaviors including number of partners and condomless sex declined over the period of the study. The incidence of syphilis was similar among those taking pre-exposure prophylaxis and those who were not. 28 Data from San Francisco's demonstration project also suggest that the number of risk behaviors and STIs did not increase. 66 67 On the other hand, early data from the Australian Victorian PrEP demonstration project, although outside of the search period for this review, suggest an increase in risk compensation. Over the first 12 months of the study, self reported condom use declined concomitantly with a significant increase in the incidence of STIs from 43.2 per 100 person years at months 0-3 to 119.8 per 100 person years at months 3-12 (incidence rate ratio 2.77, 1.52 to 5.56). 68 However, the study had a small sample size of 114 and data on STI rates before study entry were not available.
Similar increases in STI rates were reported in the US based Kaiser cohort of pre-exposure prophylaxis users (although also outside of the search period for this review). Over the first year, rectal chlamydia positivity increased from 0.9% to 2.5% (P=0.012) and urethral gonorrhea positivity increased from 7.7% to 14.1% (P<0.001), and data from Seattle show a decline in condom use and increase in STI diagnoses after prophylaxis was started. 69 Overall, these studies are difficult to interpret because the observations might be explained by a range of factors, including changing risk behavior, increased detection of STIs because of more screening, or unrelated changes in STI transmission dynamics in the wider population. However, to date, no large increases in the incidence of STIs have been attributed to pre-exposure prophylaxis, and such prophylaxis may create opportunities for STI testing and counseling, and for contemplation of sexual goals and risks, which might mitigate risk compensation. 70 Pregnancy, contraception, and pre-exposure prophylaxis FEM-PrEP and Partners PrEP investigated the effectiveness of oral contraception and pre-exposure prophylaxis when taken simultaneously to investigate whether one might affect the other. Current evidence suggests that preexposure prophylaxis does not affect the effectiveness of injectable contraception 71 and injectable contraception does not affect the efficacy of oral prophylaxis, 72 although numbers are small.
Data indicate that oral pre-exposure prophylaxis does not have an adverse impact on fertility or pregnancy. 73 In the Partners PrEP study, 431 pregnancies occurred with no difference in the incidence or loss of pregnancy, preterm birth, congenital abnormalities, or intrauterine growth between the study arms. However, prophylaxis was discontinued when pregnancy was confirmed, so data on the safety of TDF-FTC in HIV positive pregnant women may be
Risk behavior
It has been proposed that pre-exposure prophylaxis might lead to risk compensation, whereby people taking these drugs might have higher risk sexual behavior because the risk of HIV infection is no longer thought to be relevant. Such a behavior change might increase the risk of other STIs, particularly among groups that already have a disproportionately high incidence of STIs, such as men who have sex with men. Studies have investigated the possibility of risk compensation by collecting information about reported condom use and partner numbers and using diagnosed STIs as an objective measurement of risk.
However, studies exploring risk compensation are difficult to design because self reported behavioral data are subject to reporting bias, such data may vary within and between individuals, and reporting may vary across the study period. When used as a marker of risk compensation, the incidence of STIs may be affected by increased frequency of testing during the study, the types of tests used (for example, the use of dual tests for chlamydia and gonorrhea may increase detection rates of gonorrhea), changes in background population level incidences of STIs, and other simultaneous interventions such as health promotion messages. 61 Therefore, it is important to monitor behavioral and biological markers of risk compensation, but inferring associations at the population level between the use of prophylaxis and increased risk behavior is fraught with difficulty in the context of general increases in risk behaviors 62 and increases in STIs. 63 Data are available from RCTs of pre-exposure prophylaxis, although these RCTs were not powered to detect differences in sexual risk or STIs. Furthermore, participants in RCTs do not know whether they are taking the active drug so there is no expectation that they will modify their behavior in the same way that would happen in the real world. As such, RCTs provide only limited evidence about risk compensation. Fonner and colleagues found no difference in condom use or partner numbers between study arms, and no change or only small increases in condom use and decrease in partners over time among the RCTs of MSM, heterosexuals, and people who inject drugs. 18 However, meta-analysis was not possible owing to the heterogeneity of the studies. The IAVI Kenya study, which included men who have sex with men, was the only trial to report an increase in sexual partners from baseline to follow-up (from three at baseline to four at month 4), but partners may have been under-reported at baseline. 31 Open label studies and demonstration projects published after the Fonner review provide better evidence on risk compensation because patients know whether they are taking the drug and are often aware of the effectiveness of prophylaxis in preventing HIV infection. Risk compensation may be more likely in this instance. However, the data are conflicting. On the one hand, several studies suggest no evidence of risk compensation. The PROUD study showed no difference between the immediate and deferred (no prophylaxis) groups in the total number of sexual partners (P=0.57) at one year or in the frequency of overall bacterial STIs (P=0.74). 64 However, a greater proportion of the immediate group reported receptive anal sex without a condom with 10 or more partners
Guidelines
In light of the strong evidence for its efficacy, pre-exposure prophylaxis is increasingly being incorporated into national HIV prevention guidance-for example, in the US, 89 Europe, 90 Kenya, South Africa, and Brazil (table 2) . Guidelines are being prepared in the UK. World Health Organization guidelines recommend that oral p rophylaxis containing TDF should be offered to all people at substantial risk of HIV infection. 91 Substantial risk is provisionally defined as an HIV incidence of about 3 per 100 person years or more in the absence of p rophylaxis, although countries might not have accurate incidence data for relevant populations. Men who have sex with men and transgender women in the placebo arms of diverse trials routinely had incidence rates that exceeded 3.0 per 100 person years, as have cohorts of sexually active adolescent girls and young women in Africa.
There are only small differences between these guidelines in terms of drug, regimen, and eligibility criteria. The Centers for Disease Control issued guidelines in 2014 that recommended the use of daily oral prophylaxis with FTC-TDF for MSM, heterosexual women and men, and injecting drug users. 89 The European AIDS Clinical Society (EACS) guidelines recommend the use of oral FTC-TDF for HIV negative MSM and transgender people "at risk of HIV." 90 The guidelines define "at risk" for these populations as inconsistency in the use of condoms with casual partners or HIV positive partners who are not on treatment. EACS advises clinicians to consider the use of oral prophylaxis in HIV negative heterosexual men and women at risk of HIV. The recommended regimen is daily, but an "on demand" regimen as used in the IPERGAY trial is also recommended for MSM.
Emerging treatments
Several alternative prophylactic drugs and delivery modalities are being investigated in animal and human studies. Examples include long acting preparations, vaginal rings and gels, and alternative drug regimens. A search of the AVAC (Global Advocacy for HIV Prevention) HIV Prevention Research & Development Database (https://www.avac.org/pxrd), which is a comprehensive source of information on biomedical HIV prevention clinical trials, found four phase I-III trials listed as planned and five ongoing phase I-III trials. These studies include oral, long acting injectable, and topical formulations. A large number of demonstration and open label studies are planned or ongoing.
Three non-oral products have been or will be evaluated for efficacy. Tenofovir formulated as a vaginal gel and administered before and after sex showed modest effectiveness in reducing HIV and herpes simplex virus type 2 in one trial, 96 and this result was supported by a secondary analysis from an efficacy trial assessing daily tenofovir gel. 97 An intravaginal ring that releases the non-nucleoside reverse transcriptase inhibitor dapivmore informative for clinical decisions about whether to continue prophylaxis in pregnancy in light of the ongoing risk of HIV infection. A recent review indicated no safety reason to withhold prophylaxis during pregnancy, 74 and data show that the risk of acquiring HIV is increased in pregnancy, highlighting the importance of providing effective HIV prevention interventions for pregnant women. 75 
Cost effectiveness
Cost effectiveness studies are mainly based on data from the US. They suggest that pre-exposure prophylaxis can be cost effective and have significant budgetary impact, particularly among the highest risk men who have sex with men. Two models from the United Kingdom concluded that prophylaxis is cost effective when targeted at the highest risk men who have sex with men if drug prices are reduced (conference poster (reference 85)), 3 85 and a study using a third model concluded that this would also be the case in the Netherlands. 86 Cost effectiveness studies are context and epidemic specific and need to consider local factors. Key determinants have been found to include the incidence of HIV in the target group, patient adherence, levels of condomless sex, and numbers of sexual partners. The cost effectiveness of pre-exposure prophylaxis is strongly affected by the cost of prophylactic drugs, which is expected to fall with the growing availability of generic formulations. However, this is partly counterbalanced by parallel expected falls in HIV antiretroviral drugs, which are the primary costs avoided when prophylaxis is effective.
Cost effectiveness studies have highlighted that the scale-up of pre-exposure prophylaxis would be challenging in countries that have to pay the full price for the branded drug. Roll out will be particularly challenging where the infrastructure for regular HIV and STI screening is lacking. The drugs were licensed for use for prophylaxis five years ago, and an increasing number of countries are embarking on national programs, with others having approved reimbursement. However, coverage is not universal within many countries and key groups may not be accessing prophylaxis owing to barriers such as cost, knowledge, and stigma. 87 
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QUESTIONS FOR FUTURE RESEARCH
• How does the inclusion of pre-exposure prophylaxis in the wider HIV prevention strategy affect the incidence of HIV at the population level? • Will pre-exposure prophylaxis have an effect on the incidence of sexually transmitted infections and antiretroviral resistance at the population level? • How can we target pre-exposure prophylaxis most appropriately to attain optimal population level impact at a manageable cost? • Are there better alternatives to co-formulated tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) as preexposure prophylaxis? • What strategies can be used to maximize adherence to preexposure prophylaxis? • In epidemics where the incidence of HIV is declining, is there a point at which pre-exposure prophylaxis is no longer a cost effective addition to the HIV prevention package?
HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS ARTICLE
No patients were involved in the creation of this article.
Another candidate is maraviroc, a CCR5 inhibitor that was investigated for safety and acceptability in the NEXTPrEP/HPTN 069 study. 101 Maraviroc has few known side effects and a resistance profile that does not overlap with commonly used treatments for HIV. In the NEXT-PrEP study, maraviroc was given alone or in combination with emtricitabine or tenofovir, with FTC-TDF as a control. Explant data from the NEXT-PrEP study demonstrated higher levels of HIV replication in rectal tissue from the maraviroc group than in those treated with maraviroc paired with another antiretroviral (conference presentation). 102 There were also two seroconversions in the maraviroc group in spite of high levels of drug in the tissue. These preliminary data are not encouraging and there are no current plans to develop maraviroc as a prophylactic agent.
Many other HIV prevention modalities are under investigation, including a preventive HIV vaccine and the use of monoclonal antibodies. These are outlined in fig 4 but fall outside the scope of this review.
irine showed modest protection in two trials, 98 99 and it is now being evaluated in open label studies. The long acting integrase inhibitor cabotegravir administered every two months as a 3 mL intramuscular injection is being evaluated in two efficacy trials. Details of these studies fall outside the scope of this review.
Oral prophylaxis drug candidates need to have high bioavailablity or good penetration to the genital mucosa. A clinical limitation of FTC-TDF is that high plasma concentrations of tenofovir are needed to achieve adequate intracellular penetration, which can lead to worsening renal impairment in those with pre-existing disease. Tenofovir alafenamide (TAF) has greater intracellular bioavailability, and it has been shown that lower doses can be used to achieve the same therapeutic benefit when used for HIV treatment, with less risk of an effect on renal function or bone mineral density. The effectiveness of TAF combined with FTC is currently being evaluated in the DISCOVER trial. misconception that prophylaxis is not effective among heterosexual women. Only one trial has been conducted in people who inject drugs; although it demonstrated effectiveness in HIV prevention, it has not been possible to separate the reduction in the risk of sexual acquisition from the possible effect on reducing intravenous blood borne transmission. An oral event based regimen has been evaluated only in men who have sex with men, and pharmacokinetic studies have shown that drug concentrations of tenofovir are higher in rectal than in vaginal tissue. Guidelines do not currently recommend event based regimens for other risk groups. Oral FTC-TDF prophylaxis has been shown to be extremely safe, with minimal effects on kidney, bone, or pregnancy outcomes; there is no evidence that its effectiveness has been reduced by risk compensation during open label and programmatic follow-up. However, it is too early to assess the impact of its rollout on the incidence of STIs at a population level, and any changes in STI incidences will be difficult to disentangle from temporal increases in STIs in the wider population.
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Combination prevention strategies
It has long been argued that a successful public health strategy to prevent HIV requires a combination approach because of the complexities involved, and modeling studies support the idea that such an approach is essential to eliminate HIV. [103] [104] [105] Therefore, pre-exposure prophylaxis is not being thought of in isolation, and studies are under way to explore what the optimal prevention packages might look like, including behavioral risk reduction strategies and treatment as prevention alongside prophylaxis ( fig 5) .
Conclusion
Evidence shows that oral FTC-TDF prophylaxis is highly effective in reducing the risk of HIV acquisition across different types of sexual exposure and dosing schedules, in different country contexts and epidemics, and in both sexes. Although only one small trial has assessed tenofovir monotherapy in men who have sex with men, there is high quality evidence for its effectiveness in reducing heterosexual transmission, contrary to the common Many challenges remain, including improving access and adherence to pre-exposure prophylaxis and defining the optimal combination prevention program. San Francisco's experience has shown that early adoption of pre-exposure prophylaxis can be slow, but also that subsequent rapid uptake can have a substantial impact on the incidence of HIV. Therefore, clinicians have a duty of care to inform those at risk of acquiring HIV about the benefits of prophylaxis. Healthcare providers' knowledge of pre-exposure prophylaxis is variable. 106 The successes in San Francisco and London may reflect local awareness of, and prioritization and investment in, pre-exposure prophylaxis. Policy makers need to be aware of local policies and provide training for clinicians who are involved in prophylactic care to ensure that access is fair and equitable and that structural barriers to access such as knowledge, stigma, and discrimination are challenged.
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